CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer - PubMed
3 days ago
- #breast cancer
- #CD44v9
- #antibody-drug conjugate
- CD44v9 is identified as a promising therapeutic target for antibody-drug conjugates (ADCs) in advanced breast cancer.
- A chimeric monoclonal antibody against CD44v9 (clone SUM24.1, IgG1) was developed and conjugated to monomethyl auristatin F (MMAF).
- CD44v9 is highly expressed in aggressive breast cancers but absent in most normal tissues, making it a tumor-specific target.
- The anti-CD44v9-MMAF demonstrated potent cytotoxicity in vitro and dose-dependent tumor inhibition in vivo with minimal systemic toxicity.
- CD44v9 expression persists in trastuzumab deruxtecan-, sacituzumab govitecan-, and T-DM1-resistant models, remaining sensitive to CD44v9-targeted therapy.
- The findings support the development of CD44v9-directed ADCs for treatment-refractory breast cancer patients.